Abstract
Introduction
Early disease control with disease-modifying drugs is important for improving the
prognosis of multiple sclerosis (MS) in children. Dimethyl fumarate (DMF) is an oral
disease-modifying drug for MS in adults with relatively stable disease; however, its
use in young children has not been heavily documented in the current literature. We
report the case of a pediatric patient with relapsing-remitting MS who was treated
with DMF.
Case report
A 3-year-old boy with a history of common cold symptoms developed unsteadiness and
somnolence. Magnetic resonance imaging revealed multiple white matter lesions. Symptoms
were recurrent, and DMF was prescribed at 6 years of age due to a relapse episode
with oculomotor disability and facial paralysis. However, disease progression continued,
and new lesions were noted at age 7; thus, the dose of DMF was increased to 240 mg/day.
No relapse has been observed for over three years; sequelae or severe side effects
were absent.
Conclusions
DMF may be a useful oral disease-modifying drug for preventing recurrence in young
children with MS.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Brain and DevelopmentAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- ParadigMS Group. A basic overview of multiple sclerosis immunopathology.Eur J Neurol. 2015; 22: 3-13
- Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.Arch Neurol. 2009; 66: 54-59
- Pediatric multiple sclerosis: a review.Adv Pediatr. 2019; 66: 209-229
- Pediatric multiple sclerosis: Cognition and mood.Neurology. 2016; 87: S82-S87
- Multiple sclerosis – a review.Eur J Neurol. 2019; 26: 27-40
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria.Ann Neurol. 2011; 69: 292-302
- 2010 McDonald criteria for diagnosing pediatric multiple sclerosis.Ann Neurol. 2012; 72: 211-223
- Oral therapies for multiple sclerosis.Cold Spring Harb Perspect Med. 2019; 9a032011
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.N Engl J Med. 2018; 379: 1017-1027
- Dimethyl fumarate: a review in relapsing-remitting MS.Drugs. 2016; 76: 243-254
- Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis.Front Neurol. 2021; 11606418
- Isolated trochlear nerve palsy in patients with multiple sclerosis.Neurology. 1999; 53: 877-879
Article info
Publication history
Published online: January 17, 2022
Accepted:
December 30,
2021
Received in revised form:
December 9,
2021
Received:
August 12,
2021
Identification
Copyright
© 2022 The Japanese Society of Child Neurology Published by Elsevier B.V. All rights reserved.
